| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05994690 | CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de… | Acute Myeloid Leukemia in Children | Recruiting |
| NCT05327894 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or… | Acute Lymphoblastic Leukemia | Recruiting |
| Phase 2 | |||
| NCT06262438 | CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+… | Acute Myeloid Leukemia in Children | Recruiting |
| Phase 1/2 | |||
| NCT05658640 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or… | Acute Lymphoblastic Leukemia, in Relapse | Recruiting |
| NCT05745714 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine… | Acute Lymphoblastic Leukemia, in Relapse | Recruiting |
| NCT05751044 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in… | Acute Lymphoblastic Leukemia | Recruiting |
| NCT04925609 | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors | Anaplastic Large Cell Lymphoma, ALK-Positive | Recruiting |
| NCT07399821 | An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma | Neuroblastoma | Recruiting |
| NCT07020260 | The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced… | Leukemia | Not Yet Recruiting |
| NCT07175415 | HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With… | Acute Lymphoblastic Leukemia | Not Yet Recruiting |
| Phase 1 | |||
| NCT06485947 | Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma | Neuroblastoma | Recruiting |
| NCT07156435 | Vyxeos® With Clofarabine for Pediatric AML | Relapsed Pediatric AML | Recruiting |
| Not specified | |||
| NCT05270096 | International Leukemia Target Board | Relapsed Hematologic Malignancy | Recruiting |